Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card? - Suppr | 超能文献

Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?

作者信息

DeCara J M, Croze S, Falk R H

出版信息

Chest. 1998 Feb;113(2):261-3. doi: 10.1378/chest.113.2.261.

DOI:10.1378/chest.113.2.261

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Generic warfarin: a cost-effective alternative to brand-name drug or a clinical wild card?

Chest. 1998 Feb;113(2):261-3. doi: 10.1378/chest.113.2.261.

2

Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.华法林用于心房颤动血栓栓塞的二级预防：生物利用度对成本和结局的影响。

Pharmacoeconomics. 2004;22(10):671-83. doi: 10.2165/00019053-200422100-00005.

3

Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.在心房颤动患者中，华法林制剂转换所带来的资源利用和成本影响。

Ann Pharmacother. 2012 Dec;46(12):1609-16. doi: 10.1345/aph.1Q472. Epub 2012 Nov 13.

4

[Atrial fibrillation: new anticoagulants are more effective and safer, but expensive].

Praxis (Bern 1994). 2014 Jun 18;103(13):785-6. doi: 10.1024/1661-8157/a001681.

5

Barriers to the use of warfarin: potential solutions.华法林使用的障碍：潜在解决方案。

J Interv Card Electrophysiol. 2004;10 Suppl 1:17-20. doi: 10.1023/B:JICE.0000011341.67214.2e.

6

Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation.非瓣膜性心房颤动卒中预防的成本效益

JAMA. 1996 Mar 27;275(12):909; author reply 910. doi: 10.1001/jama.275.12.909.

7

Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.使用美国心房颤动患者的药物计量学估算预测达比加群酯通用药物与品牌药物的成本效益。

Clin Transl Sci. 2020 Mar;13(2):352-361. doi: 10.1111/cts.12719. Epub 2020 Feb 13.

8

New anticoagulants offer options beyond warfarin to reduce stroke risk.

JAMA. 2012 Nov 7;308(17):1727-8. doi: 10.1001/jama.2012.14623.

9

Brand name versus generic warfarin: a systematic review of the literature.品牌名药物华法林与通用名药物华法林的对比：文献系统评价。

Pharmacotherapy. 2011 Apr;31(4):386-93. doi: 10.1592/phco.31.4.386.

10

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.达比加群酯与维生素K拮抗剂预防心房颤动患者卒中的成本效益分析：法国医保支付方视角

Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.

引用本文的文献

1

Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.心血管疾病中使用的仿制药和品牌药的临床等效性：一项系统评价和荟萃分析。

JAMA. 2008 Dec 3;300(21):2514-26. doi: 10.1001/jama.2008.758.

2

Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes.华法林用于心房颤动血栓栓塞的二级预防：生物利用度对成本和结局的影响。

Pharmacoeconomics. 2004;22(10):671-83. doi: 10.2165/00019053-200422100-00005.

3

Barriers to the use of warfarin: potential solutions.华法林使用的障碍：潜在解决方案。

J Interv Card Electrophysiol. 2004;10 Suppl 1:17-20. doi: 10.1023/B:JICE.0000011341.67214.2e.

4

Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.使用仿制药不足的经济后果：来自医疗补助计划的证据及对处方药福利计划的启示

Health Serv Res. 2003 Aug;38(4):1051-63. doi: 10.1111/1475-6773.00162.